Xie Y, Zheng J, Li S, Li H, Zhou Y, Zheng W, et al
References Arai, M., Imai, H., Koumura, T., Yoshida, M., Emoto, K., Umeda, M., Chiba, N., and Nakagawa, Y
Researchers are responsible for compliance with all applicable laws and institutional guidelines
[6] [11] Precautions and warnings (not formal contraindications) include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and previous pancreatitis
Despite promising preliminary findings, there remains a need for larger, well-designed studies that can accurately assess the long-term safety, optimal doses, and specific populations that may benefit most from supplementation
A 2022 review in Diabetes Care noted that GI motility changes from GLP-1 receptor agonists can cause both accelerated small bowel transit in some individuals and paradoxical constipation in others, depending on regional receptor distribution [5]